
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Quantexa Recognized in Chartis’s Inaugural Financial Crime and Compliance 50 Rankings as Top Ranked Solution Provider

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

